SUPERNUS PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$58.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$58.37M, a 359.44% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$2.29M.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $22.50M.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was -$11.83M.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$38.55M, a 152.19% decline from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was $73.86M, a 5512.84% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was $1.32M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|
| 2026-06-30 | -$58.37M 10-Q · filed 2026-08-03 | -$60.66M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | -$2.29M 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | -$38.55M 10-K · filed 2026-03-02 | ||
| 2025-06-30 | $22.50M 10-Q · filed 2026-08-03 | $10.67M 10-Q · filed 2026-08-03 | |
| 2025-03-31 | -$11.83M 10-Q · filed 2026-05-05 | ||
| 2024-12-31 | $73.86M 10-K · filed 2026-03-02 | ||
| 2023-12-31 | $1.32M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |